Experience

Davis Polk advised the placing agents for the top-up placement of up to 97,000,000 shares in Innovent Biologics, Inc. for a total consideration of approximately HK$2.4 billion. Davis Polk…

Davis Polk advised the underwriters in connection with the SEC-registered offering by BioXcel Therapeutics, Inc. of 2,303,030 shares of its common stock. The common stock is listed on the…

Davis Polk advised the underwriters in connection with an SEC-registered offering by AbbVie Inc. of €1.4 billion aggregate principal amount of senior notes in two series, consisting of €750…

Davis Polk is acting as special tax counsel to Danaher Corporation on the separation of its dental division into a new publicly traded company called Envista Holdings Corporation and the …

Davis Polk advised the underwriter in connection with the SEC-registered offering by PTC Therapeutics, Inc. of 2,475,248 shares of its common stock and the initial purchaser in a concurrent…

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Heska Corporation of an aggregate principal amount of $86.25 million of its 3.750% convertible senior…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with an SEC-registered offering of common stock by iRhythm Technologies, Inc…

Davis Polk advised the underwriters in connection with a $202.5 million public offering of common stock by Turning Point Therapeutics, Inc. Turning Point Therapeutics’ common stock is…

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Insulet Corporation of $800 million principal amount of 0.375% convertible senior notes due 2026,…

Davis Polk advised the joint book-running managers in connection with the SEC-registered offering by Deciphera Pharmaceuticals, Inc. of 10,810,810 shares of common stock for gross proceeds…